Seminars in Hematology
Volume 43 , Pages S3-S7 , April 2006

Overview of Inhibitors

  • Jan Astermark

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jan Astermark, MD, PhD, Department of Hematology and Coagulation Disorders, Malmö University Hospital, SE-205 02 Malmö, Sweden.

References 

  1. Kasper CK . Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians . Treatment of Hemophilia Monograph Series, No. 34 . Montreal, Québec, Canada: World Federation of Hemophilia; 2004;
  2. DiMichele D . Inhibitors (Resolving diagnostic and therapeutic dilemmas) . Haemophilia . 2002;8:280–287
  3. DiMichele D , Rivard G , Hay C , Antunes S . Inhibitors in haemophilia (Clinical aspects) . Haemophilia . 2004;10(suppl 4):140–145
  4. Gill JC . The role of genetics in inhibitor formation . Thromb Haemost . 1999;82:500–504
  5. Oldenburg J , El-Maarri O , Schwaab R . Inhibitor development in correlation to factor VIII genotypes . Haemophilia . 2002;8(suppl 2):23–29
  6. Kasper CK , Aledort L , Aronson D , Counts R , Edson JR , van Eys J , et al.   Proceedings (A more uniform measurement of factor VIII inhibitors) . Thromb Diath Haemorrh . 1975;34:612
  7. Verbruggen B , Novakova I , Wessels H , Boezeman J , van den Berg M , Mauser-Bunschoten E . The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability . Thromb Haemost . 1995;73:247–251
  8. Wight J , Paisley S . The epidemiology of inhibitors in haemophilia A (A systematic review) . Haemophilia . 2003;9:418–435
  9. Scharrer I , Bray GL , Neutzling O . Incidence of inhibitors in haemophilia A patients—A review of recent studies of recombinant and plasma-derived factor VIII concentrates . Haemophilia . 1999;5:145–154
  10. Ljung R , Petrini P , Tengborn L , Sjörin E . Haemophilia B mutations in Sweden (A population-based study of mutational heterogeneity) . Br J Haematol . 2001;113:81–86
  11. Addiego J , Kasper C , Abildgaard C , Hilgartner M , Lusher J , Glader B , et al.   Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII . Lancet . 1993;342:462–464
  12. The Recombinate Study Group Bray GL , Gomperts ED , Courter S , Gruppo R , Gordon EM , Manco-Johnson M , et al.   A multicenter study of recombinant factor VIII (Recombinate) (Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A) . Blood . 1994;83:2428–2435
  13. de Biasi R , Rocino A , Papa ML , Salerno E , Mastrullo L , De Blasi D . Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates . Thromb Haemost . 1994;71:544–547
  14. Lorenzo JI , Lopez A , Altisent C , Aznar JA . Incidence of factor VIII inhibitors in severe haemophilia (The importance of patient age) . Br J Haematol . 2001;113:600–603
  15. van der Bom JG , Mauser-Bunschoten EP , Fischer K , van den Berg HM . Age at first treatment and immune tolerance to factor VIII in severe hemophilia . Thromb Haemost . 2003;89:475–479
  16. Santagostino E , Mancuso ME , Rocino A , Mancuso G , Mazzucconi MG , Tagliaferri A , et al.   Environmental risk factors for inhibitor development in children with haemophilia A (A case-control study) . Br J Haematol . 2005;130:422–427
  17. Sharathkumar A , Lillicrap D , Blanchette VS , Kern M , Leggo J , Stain AM , et al.   Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A . J Thromb Haemost . 2003;1:1228–1236
  18. Peerlinck K , Arnout J , Gilles JG , Saint-Remy JM , Vermylen J . A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate . Thromb Haemost . 1993;69:115–118
  19. Peerlinck K , Arnout J , Di Giambattista M , Gilles JG , Laub R , Jacquemin M , et al.   Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate . Thromb Haemost . 1997;77:80–86
  20. Rosendaal FR , Nieuwenhuis HK , van den Berg HM , Heijboer H , Mauser-Bunschoten EP , van der Meer J , et al.  Dutch Hemophilia Study Group   A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands . Blood . 1993;81:2180–2186
  21. Josic D , Buchacher A , Kannicht C , Lim YP , Loster K , Pock K , et al.   Degradation products of factor VIII which can lead to increased immunogenicity . Vox Sang . 1999;77(suppl 1):90–99
  22. Saenko E , Josic D , Stadler M , Sarafanov A , Lim Y , Shima M , et al.   Molecular modifications in factor VIII concentrates produced from different plasma pools . Thromb Res . 2001;101:501–511
  23. Astermark J , Ekman M , Berntorp E . No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro (A study of plasma-derived and recombinant products) . Br J Haematol . 1997;99:289–294
  24. Grosset AB , McGregor JR , Samlowski WE , Rodgers GM . Immunosuppressive effects of factor IX products (An in vitro study) . Haemophilia . 1999;5:416–425
  25. Auerswald G , Spranger T , Brackmann HH . The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients . Haematologica . 2003;88: EREPO5
  26. Warrier I , Ewenstein BM , Koerper MA , Shapiro A , Key N , DiMichele D , et al.   Factor IX inhibitors and anaphylaxis in hemophilia B . J Pediatr Hematol Oncol . 1997;19:23–27
  27. Hay CR , Ollier W , Pepper L , Cumming A , Keeney S , Goodeve AC , et al.  UKHCDO Inhibitor Working Party   HLA class II profile (A weak determinant of factor VIII inhibitor development in severe haemophilia A) . Thromb Haemost . 1997;77:234–237
  28. Oldenburg J , Picard JK , Schwaab R , Brackmann HH , Tuddenham EG , Simpsom E . HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII . Thromb Haemost . 1997;77:238–242
  29. Addiego JE , Kasper C , Abildgaard C , Lusher J , Hilgartner M , Glader B , et al.   Increased frequency of inhibitors in African American hemophilia A patients . Blood . 1994;1(suppl):239a; (abstr)
  30. Astermark J , Berntorp E , White GC , Kroner BL  MIBS Study Group . The Malmö International Brother Study (MIBS) (Further support for genetic predisposition to inhibitor development in hemophilia patients) . Haemophilia . 2001;7:267–272
  31. Saint-Remy J-MR , Lacroix-Desmazes S , Oldenburg J . Inhibitors in haemophilia (Pathophysiology) . Haemophilia . 2004;10(suppl 4):146–151
  32. Astermark J , Oldenburg J , Escobar M , White GC , Berntorp E  Malmö International Brother Study study group . The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A . Haematologica . 2005;90:924–931
  33. Rick ME , Walsh CE , Key NS . Congenital bleeding disorders . Hematology . 2003;559–574 Am Soc Hematol Educ Program
  34. McKenna R . Factor IX . 2005; Available at: http://www.emedicine.com/MED/topic364.htm. Accessed August 2, 2005
  35. Warrier I , Lusher JM . Development of anaphylactic shock in haemophilia B patients with inhibitors . Blood Coagul Fibrinolysis . 1998;9(suppl 1):S125–S128
  36. Dahlbäck B . Blood coagulation and its regulation by anticoagulant pathways (Genetic pathogenesis of bleeding and thrombotic diseases) . J Intern Med . 2005;257:209–223
  37. MRC haemostasis and thrombosis database resource sites . The molecular pathology of haemophilia A . 2003; Available at: http://europium.csc.mrc.ac.uk/WebPages/Database/Review/Review_txt.html. Accessed December 20, 2005
  38. Tengborn L , Hansson S , Fasth A , Lübeck P-O , Berg A , Ljung R . Anaphylactoid reactions and nephrotic syndrome—A considerable risk during factor IX treatment in patients with haemophilia B and inhibitors (A report on the outcome in two brothers) . Haemophilia . 1998;4:854–859
  39. Oldenburg J , Schröder J , Brackmann HH , Müller-Reible C , Schwaab R , Tuddenham E . Environmental and genetic factors influencing inhibitor development . Semin Hematol . 2004;41(suppl 1):82–88
  40. Hausl C , Ahmad RU , Schwarz HP , Muchitsch EM , Turecek PL , Dorner F , et al.   Preventing restimulation of memory B cells in hemophilia A (A potential new strategy for the treatment of antibody-dependent immune disorders) . Blood . 2004;104:115–122

 This article is based in part on the proceedings from an educational symposium held at the World Federation of Hemophilia World Congress 2004 in Bangkok, Thailand. Both the symposium and this manuscript were supported by Baxter Healthcare Corporation.

PII: S0037-1963(06)00052-7

doi: 10.1053/j.seminhematol.2006.03.006

Seminars in Hematology
Volume 43 , Pages S3-S7 , April 2006

Article Tools

* Image Usage & Resolution